Internal Medicine

Internet-delivered CBT may be an efficient and convenient means for addressing behaviors that exacerbate atopic dermatitis-related symptoms.

More and more individuals are becoming diagnosed with atrial fibrillation. But the research to halt this crisis is not quite there yet.

Vonoprazan has shown more potent acid inhibitory effects than PPI.

Pegcetacoplan outperformed competitor in a phase 3 head-to-head study.

The anticoagulant did not improve clinical outcomes when compared with prophylactic anticoagulation.

New data suggest 90 days following an initial ACS event is the greatest time of likelihood for another high-risk event. How can this inform cardiovascular research?

There is no clear threshold for consumption leading to an AFib event.

Patients with a preserved ejection fraction saw a significant reduction in risk for cardiovascular-related adverse events and mortality.

Investigators discuss recently-published secondary sex-based assessments into PCI treatment, as well as their contribution to cardiovascular research action points that lessen the field's disparities.

Patients on atorvastatin experienced similar rates of adjudicated venous thromboembolism and all-cause mortality compared to placebo.

The 1-year follow-up of the REALITY trial presented at ACC undermines previously reported 30-day findings showing noninferiority to liberal transfusions.

DARE-19 data show a slight improvement in outcomes among hospitalized COVID-19 patients receiving the SGLT-2 inhibitor—showing the cardiovascular drug class is safe in patients with the pandemic virus.

A post-hoc analysis sought to elucidate the contradictory results between the STRENGTH and REDUCE-IT trials.

Older patients who maintained the multi-domain rehabilitation program saw improvements in various markers of physical function.

Investigators discuss observed outcomes in females with high-risk PCI treatment, and their continued underrepresentation in pharmacologic studies.

Improvements in patient symptoms, function, and quality of life were not sustained once treatment was discontinued.

Though the combination heart failure therapy did provide overall benefit versus ramipril in post-heart attack patients, the rate of events reduced was not considered significant.

The first episode of the Heart Trials podcast series focuses on new ACC 2021 research into aspirin dosages for reduced cardiovascular event risk.

FIX activity was similar in participants without and with pre-existing neutralizing antibodies.

Patients who received 2 mg or 4 mg of baricitinib maintained vIGA-AD scores through 68 weeks of treatment.

Sickle cell patients in rural areas may actually benefit from telemedicine practices and access to satellite clinics.

The newest findings show the TSLP inhibitor is beneficial over 52 weeks in patients aged 12-80 years old.

Bayer has submitted a New Drug Application for the mineralocorticoid receptor antagonist.

The presence of extra-intestinal manifestations in biologic-naïve anti-TNF patients with Crohn’s disease was a predictor of disease severity.

The majority of adverse effects reported were considered mild.